The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab ... unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The approval was supported by data ...
approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination therapy for mesothelioma, a cancer in the linings of internal organs. Accordingly ...
Results that may be inaccessible to you are currently showing.